Elicio Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Elicio Therapeutics, Inc. (ELTX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 2.35 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-13
- Elicio Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 0.00 shares.
- Elicio Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 2.35K shares, a 5.44% increase year-over-year.
- Elicio Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 7.30K shares, a 102.27% increase year-over-year.
- Elicio Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 48.88K shares, a 53.51% decline year-over-year.
- Elicio Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 58.41K shares, a 71.39% decline from fiscal 2024.
- Elicio Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 204.17K shares, a 97.97% increase from fiscal 2023.
- Elicio Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 103.13K shares, a 96.26% decline from fiscal 2022.
- Elicio Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 2.76M shares, a 1357.86% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | 2.35K shares 10-Q · filed 2026-08-13 | 9.65K shares derived: sum of 3 quarters · filed 2026-08-13 | 58.53K shares derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | 2.35K shares 10-Q · filed 2026-05-11 | 9.65K shares derived: sum of 2 quarters · filed 2026-05-11 | 58.53K shares derived: sum of 3 quarters · filed 2026-05-11 | 58.53K shares derived: sum of 4 quarters · filed 2026-05-11 |
| 2025-12-31 | 7.30K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | 56.18K shares derived: sum of 2 quarters · filed 2026-03-12 | 56.18K shares derived: sum of 3 quarters · filed 2026-03-12 | 58.41K shares 10-K · filed 2026-03-12 |
| 2025-09-30 | 48.88K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | 48.88K shares derived: sum of 2 quarters · filed 2025-11-13 | 51.11K shares 10-Q · filed 2025-11-13 | 54.72K shares derived: sum of 4 quarters · filed 2025-11-13 |
| 2025-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 2.23K shares 10-Q · filed 2025-08-07 | 5.83K shares derived: sum of 3 quarters · filed 2025-08-07 | 110.97K shares derived: sum of 4 quarters · filed 2025-08-07 |
| 2025-03-31 | 2.23K shares 10-Q · filed 2025-05-13 | 5.83K shares derived: sum of 2 quarters · filed 2025-05-13 | 110.97K shares derived: sum of 3 quarters · filed 2025-05-13 | 125.56K shares derived: sum of 4 quarters · filed 2025-05-13 |
| 2024-12-31 | 3.61K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | 108.75K shares derived: sum of 2 quarters · filed 2025-03-31 | 123.33K shares derived: sum of 3 quarters · filed 2025-03-31 | 204.17K shares 10-K · filed 2025-03-31 |
| 2024-09-30 | 105.14K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | 119.72K shares derived: sum of 2 quarters · filed 2024-11-13 | 200.56K shares 10-Q · filed 2024-11-13 | 284.11K shares derived: sum of 4 quarters · filed 2024-11-13 |
| 2024-06-30 | 14.59K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | 95.42K shares 10-Q · filed 2024-08-13 | 178.97K shares derived: sum of 3 quarters · filed 2024-08-13 | 178.26K shares derived: sum of 4 quarters · filed 2024-08-13 |
| 2024-03-31 | 80.84K shares 10-Q · filed 2024-05-15 | 164.39K shares derived: sum of 2 quarters · filed 2024-05-15 | 163.68K shares derived: sum of 3 quarters · filed 2024-05-15 | 137.41K shares derived: sum of 4 quarters · filed 2024-05-15 |
| 2023-12-31 | 83.55K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | 82.84K shares derived: sum of 2 quarters · filed 2024-03-29 | 56.57K shares derived: sum of 3 quarters · filed 2024-03-29 | 103.13K shares 10-K · filed 2024-03-29 |
| 2023-09-30 | -713.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -26.98K shares derived: sum of 2 quarters · filed 2023-11-13 | 19.58K shares 10-Q · filed 2023-11-13 | 1.87M shares derived: sum of 4 quarters · filed 2023-11-13 |
| 2023-06-30 | -26.27K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | 20.29K shares 10-Q · filed 2023-08-14 | 1.87M shares derived: sum of 3 quarters · filed 2023-08-14 | 2.15M shares derived: sum of 4 quarters · filed 2023-08-14 |
| 2023-03-31 | 46.56K shares 10-Q · filed 2023-05-10 | 1.89M shares derived: sum of 2 quarters · filed 2023-05-10 | 2.18M shares derived: sum of 3 quarters · filed 2023-05-10 | 2.42M shares derived: sum of 4 quarters · filed 2023-05-10 |
| 2022-12-31 | 1.85M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | 2.13M shares derived: sum of 2 quarters · filed 2023-03-17 | 2.37M shares derived: sum of 3 quarters · filed 2023-03-17 | 2.76M shares 10-K · filed 2023-03-17 |
| 2022-09-30 | 287.67K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | 523.51K shares derived: sum of 2 quarters · filed 2022-11-14 | 914.62K shares 10-Q · filed 2022-11-14 | 1.07M shares derived: sum of 4 quarters · filed 2022-11-14 |
| 2022-06-30 | 235.84K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | 626.95K shares 10-Q · filed 2022-08-15 | 783.15K shares derived: sum of 3 quarters · filed 2022-08-15 | 809.53K shares derived: sum of 4 quarters · filed 2022-08-15 |
| 2022-03-31 | 391.11K shares 10-Q · filed 2022-05-16 | 547.31K shares derived: sum of 2 quarters · filed 2022-05-16 | 573.68K shares derived: sum of 3 quarters · filed 2022-05-16 | 573.68K shares derived: sum of 4 quarters · filed 2022-05-16 |
| 2021-12-31 | 156.20K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | 182.58K shares derived: sum of 2 quarters · filed 2022-03-30 | 182.58K shares derived: sum of 3 quarters · filed 2022-03-30 | 189.39K shares 10-K · filed 2022-03-30 |
| 2021-09-30 | 26.38K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | 26.38K shares derived: sum of 2 quarters · filed 2021-11-12 | 33.19K shares 10-Q · filed 2021-11-12 | |
| 2021-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | 6.81K shares 10-Q · filed 2021-08-12 | ||
| 2021-03-31 | 6.81K shares 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |